A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Source:http://linkedlifedata.com/resource/pubmed/id/19723647

Clin. Cancer Res. 2009 Sep 15 15 18 5910-6

Download in:

View as

Triples

General Info

PMID
19723647